Ching-Yueh Lin1,2, Chi-Hsiang Chung3,4,5, Dennis J Matthews6, Heng-Yi Chu2,7, Liang-Cheng Chen2,7, Sung-Sen Yang4,8, Wu-Chien Chien3,4,5. 1. Department of Physical Medicine & Rehabilitation, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan. 2. School of Medicine, National Defense Medical Center, Taipei, Taiwan. 3. School of Public Health, National Defense Medical Center, Taipei, Taiwan. 4. Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan. 5. Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan. 6. Department of Physical Medicine and Rehabilitation, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, United States of America. 7. Department of Physical Medicine and Rehabilitation, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan. 8. Division of Nephrology, Department of Medicine, Tri-Service General Hospital, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan.
Abstract
OBJECTIVES: To investigate the effect of botulinum toxin A (BTA) on the development of hip dislocation and scoliosis, surgical rates for hip and spine, and mortality in cerebral palsy (CP). STUDY DESIGN: A cohort study was conducted using CP data from a Taiwan National Insurance Health Research Database. Diagnoses were defined using the International Classification of Diseases codes, 9th revision. Adjusted hazard ratios for outcomes were calculated using Cox regression analysis and adjusted for the following variables: BTA injection, sex, age, severities of CP, comorbidities, location, urbanization level, and level of care. RESULTS: A total of 1,405 CP children (670 female vs. 735 male), 281 in the BTA group and 1,124 in the controls, were followed-up for a mean of 5 years 4 months. There were no significant differences in the outcomes in both groups, in the incidence rates of hip dislocation and scoliosis, nor in the surgical rates for hip and spine surgery. Mortality rate in the BTA group was 0.49 times lower than that in the controls (p = 0.001). Moderate to severe types of CP had higher incidence rates of hip dislocation, scoliosis, hip surgery, spine surgery, and mortality. CONCLUSION: Moderate to severe types of CP had poorer outcomes in all aspects, including a higher risk of hip dislocation, scoliosis, surgical rate for hip and spine, and mortality. Although BTA injection in children with CP proved to not significantly reduce hip dislocation and scoliosis, it is considered safe as an anti-spasticity treatment and may be beneficial for survival.
OBJECTIVES: To investigate the effect of botulinum toxin A (BTA) on the development of hip dislocation and scoliosis, surgical rates for hip and spine, and mortality in cerebral palsy (CP). STUDY DESIGN: A cohort study was conducted using CP data from a Taiwan National Insurance Health Research Database. Diagnoses were defined using the International Classification of Diseases codes, 9th revision. Adjusted hazard ratios for outcomes were calculated using Cox regression analysis and adjusted for the following variables: BTA injection, sex, age, severities of CP, comorbidities, location, urbanization level, and level of care. RESULTS: A total of 1,405 CPchildren (670 female vs. 735 male), 281 in the BTA group and 1,124 in the controls, were followed-up for a mean of 5 years 4 months. There were no significant differences in the outcomes in both groups, in the incidence rates of hip dislocation and scoliosis, nor in the surgical rates for hip and spine surgery. Mortality rate in the BTA group was 0.49 times lower than that in the controls (p = 0.001). Moderate to severe types of CP had higher incidence rates of hip dislocation, scoliosis, hip surgery, spine surgery, and mortality. CONCLUSION: Moderate to severe types of CP had poorer outcomes in all aspects, including a higher risk of hip dislocation, scoliosis, surgical rate for hip and spine, and mortality. Although BTA injection in children with CP proved to not significantly reduce hip dislocation and scoliosis, it is considered safe as an anti-spasticity treatment and may be beneficial for survival.
Authors: Maria D Gonzalez-L; Carmen Martinez; Inma Bori Y Fortuny; Santiago Suso-Vergara Journal: Am J Phys Med Rehabil Date: 2017-02 Impact factor: 2.159
Authors: H Kerr Graham; Roslyn Boyd; John B Carlin; Fiona Dobson; Kevin Lowe; Gary Nattrass; Pam Thomason; Rory Wolfe; Dinah Reddihough Journal: J Bone Joint Surg Am Date: 2008-01 Impact factor: 5.284